Markets

Biotechnology Shares Rebound 2.4% on Monday, But Still on Track to End March Lower

Biotech stocks (SPSIBI) are up on average 2.4% on Monday, working to end March on a positive note. However, the sector will still be down about 15% on the month.

Early Monday morning, CNBC interviewed James Kolbert, head of health care research at Maxim Group, who said the most recent sell-off in the sector is not justified as a broad range of new drugs are coming. He sees a 'paradigm shift' in approval rates from the FDA based on a number of positive changes in the industry. He suggests investors should have biotech exposure.

Recent news that a Congressional letter sent to Gillead Sciences ( GILD ) questioned the pricing of the $1,000 hepatitis C pill Solvaldi added to selling pressure in the group over the past week. GILD is participating in the sector gains though on Monday, last up 3% at $70.60 per share.

Among the Biotech stocks advancing the most in midday Monday trade are:

BHRT + 14.6%

ASTM + 11.6%

AGIO +11.3%

GEVA + 10.2%

APPY +7.3%

ALNY +7.2%

EXAS + 6.9%

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GILD

Other Topics

Commodities